Gaining Efficiency in Clinical Trials With Cardiac Biomarkers

被引：8

作者：

Januzzi, James L., Jr. ^{[1
,2
]}

Canty, John M. ^{[3
,4
]}

Das, Saumya ^{[1
]}

DeFilippi, Christopher R. ^{[5
]}

Gintant, Gary A. ^{[6
]}

Gutstein, David E. ^{[7
]}

Jaffe, Allan ^{[8
,9
]}

Kaushik, Emily P. ^{[10
]}

Leptak, Christopher ^{[11
]}

Mehta, Cyrus ^{[12
,13
]}

Pina, Ileana ^{[14
]}

Povsic, Thomas J. ^{[15
,16
]}

Rambaran, Curtis ^{[17
]}

Rhyne, Rhonda F. ^{[18
]}

Salas, Maribel ^{[17
,19
]}

Shi, Victor C. ^{[20
]}

Udell, Jacob A. ^{[21
,22
]}

Unger, Ellis F. ^{[23
]}

Zabka, Tanja S. ^{[24
]}

Seltzer, Jonathan H. ^{[25
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Cardiol Div, Boston, MA 02115 USA

[2] Baim Inst Clin Res, Boston, MA USA

[3] Univ Buffalo, Div Cardiovasc Med, Buffalo, NY USA

[4] Western New York Hlth Care Syst, Dept Vet Affairs, Buffalo, NY USA

[5] Inova Heart & Vasc Inst, Falls Church, VA USA

[6] AbbVie Pharmaceut, Dept Integrat Pharmacol Integrated Sci & Technol, Cambridge, MA USA

[7] Janssen Pharmaceut, Cardiovasc Metab Discovery, Titusville, NJ USA

[8] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA

[9] Mayo Clin, Lab Med & Pathol, Rochester, MN USA

[10] Takeda Pharmaceut, Global Drug Safety Res & Evaluat, Boston, MA USA

[11] US FDA, Biomarker Qualificat Program, Off New Drugs, Ctr Drug Dev & Res, Silver Spring, MD USA

[12] Harvard TH Chan Sch Publ Hlth, Boston, MA USA

[13] Cytel Inc, Boston, MA USA

[14] Wayne State Univ, Detroit, MI USA

[15] Duke Univ, Duke Clin Res Inst, Durham, NC USA

[16] Duke Univ, Dept Med, Durham, NC USA

[17] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[18] Prevencio Inc, Kirkland, WA USA

[19] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[20] Novartis Pharmaceut, Basel, Switzerland

[21] Univ Toronto, Womens Coll Hosp, Cardiovasc Div, Toronto, ON, Canada

[22] Univ Toronto, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Toronto, ON, Canada

[23] US FDA, Off Cardiol Hematol Endocrinol & Nephrol, Off New Drugs, Ctr Drug Dev & Res, Silver Spring, MD USA

[24] Genentech Inc, Dev Sci Safety Assessment, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA

[25] WCG Clin & WCG ACI Clin, Bala Cynwood, PA USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2021年 / 77卷 / 15期

关键词：

biomarker; clinical trials; biobanking; ROSUVASTATIN MULTINATIONAL TRIAL; BRAIN NATRIURETIC PEPTIDE; SAMPLED BLOOD ARCHIVE; HEART-FAILURE; CORONARY; THERAPY; ANGIOGRAPHY; PREDICTION; SURVIVAL; BENEFIT;

D O I：

10.1016/j.jacc.2021.02.040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The momentum of cardiovascular drug development has slowed dramatically. Use of validated cardiac biomarkers in clinical trials could accelerate development of much-needed therapies, but biomarkers have been used less for cardiovascular drug development than in therapeutic areas such as oncology. Moreover, there are inconsistences in biomarker use in clinical trials, such as sample type, collection times, analytical methods, and storage for future research. With these needs in mind, participants in a Cardiac Safety Research Consortium Think Tank proposed the development of international guidance in this area, together with improved quality assurance and analytical methods, to determine what biomarkers can reliably show. Participants recommended the development of systematic methods for sample collection, and the archiving of samples in all cardiovascular clinical trials (including creation of a biobank or repository). The academic and regulatory communities also agreed to work together to ensure that published information is fully and clearly expressed.

引用

页码：1922 / 1933

页数：12

共 50 条

[1] Nuclear Cardiology Surrogate Biomarkers in Clinical Trials
Miller, Robert J. H.
Patel, Krishna K.
Kwiecinski, Jacek
Slipczuk, Leandro
Dweck, Marc
Newby, David E.
Chareonthaitawee, Panithaya
Slomka, Piotr
JOURNAL OF NUCLEAR MEDICINE, 2025, 66 (01) : 4 - 11
[2] Biomarkers and the design of clinical trials in cancer
Fraser, Graeme A. M.
Meyer, Ralph M.
BIOMARKERS IN MEDICINE, 2007, 1 (03) : 387 - 397
[3] Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials
Ibrahim, Nasrien E.
Gaggin, Hanna K.
Konstam, Marvin A.
Januzzi, James L., Jr.
CIRCULATION-HEART FAILURE, 2016, 9 (09)
[4] Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers
Shih, Weichung Joe
Lin, Yong
STATISTICS IN MEDICINE, 2018, 37 (05) : 687 - 709
[5] Clinical biomarkers of kinase activity: examples from EGFR inhibition trials
Krause, Mechthild
Baumann, Michael
CANCER AND METASTASIS REVIEWS, 2008, 27 (03) : 387 - 402
[6] Clinical biomarkers of kinase activity: examples from EGFR inhibition trials
Mechthild Krause
Michael Baumann
Cancer and Metastasis Reviews, 2008, 27 : 387 - 402
[7] Clinical usefulness of biomarkers in cardiac failure
Paredes C, Alejandro
Vega, Julian
de Leon, Ana
Kanacri, Andres
Castro, Pablo
Baeza, Ricardo
REVISTA MEDICA DE CHILE, 2013, 141 (12) : 1560 - 1569
[8] Integrating biomarkers in clinical trials
Buyse, Marc
Michiels, Stefan
Sargent, Daniel J.
Grothey, Axel
Matheson, Alastair
de Gramont, Aimery
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2011, 11 (02) : 171 - 182
[9] Challenges and methodology in the incorporation of biomarkers in cancer clinical trials
Wilhelm-Benartzi, Charlotte S.
Mt-Isa, Shahrul
Fiorentino, Francesca
Brown, Robert
Ashby, Deborah
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 110 : 49 - 61
[10] Cardiac safety evaluation in cancer clinical trials
Gujral, Dorothy M.
Cleator, Susan J.
Bhattacharyya, Sanjeev
EUROPEAN JOURNAL OF CANCER, 2018, 103 : 143 - 146

← 1 2 3 4 5 →